Thrombolysis in Myocardial Infarction Study Group   Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2007
NCT00526474
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

The Thrombolysis in Myocardial Infarction Study (TIMI) Group | The TIMI (Thrombolysis in Myocardial Infarction) Study Group | Thrombolysis in Myocardial Infarction (TIMI) Study Group

Active Ingredients

Drugs in Phase 3 Trials (1)

vorapaxar (zontivity) (2 trials)

Drugs in Phase 2 Trials (2)

acp-501 (1 trial)

medi6570 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 3)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Heart Diseases (Phase 2)

Infarction (Phase 3)

Ischemia (Phase 3)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 2)

Peripheral Arterial Disease (Phase 3)

Peripheral Vascular Diseases (Phase 3)

ST Elevation Myocardial Infarction (Phase 2)

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3